BJCT-BIOJECT-needle less injection product Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : BJCT-BIOJECT-needle less injection product

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: GREG FINLEY who wrote (430)	1/18/2000 10:51:00 AM
From: geewiz	of 534

Hello Greg, My enthusiasm for our platform has become more clearly focused on two product markets; Bioject as an enabling technology and optimized delivery company for use in oncology and cardiovascular fields - the therapeutic approach. Bioject as an enabling delivery and custom package company for massive inoculations of stable DNA vaccinations - the preventative approach. I bought my first shares in 94' with confidence that our products would gain ready market acceptance in the campaign to curb needle stick injuries. That was a gross miscalculation. Many of the posts over on YAHOO still hold on to this hope; I think that it may contribute to our product acceptance but there are far greater reasons to have confidence in our market dominance; although I realize this does require connecting some dots and making some conclusions of one's own! The greatest underlying assumption is that the jet injection will prove to have greater vector uptake by targeted biomass (muscle or organ) and given Powderjects' success and our own published results that is no longer a leap of faith! And the most hopeful part of this is institutional holding at a small percent of our outstanding shares. later, art

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next